Epidemiological data on postprandial glycaemia

Diabetes and Metabolism

Volumn 32, Issue HS2, 2006, Pages

  Balkau, B ^a   Eschwege E ^a  

^a INSERM   (France)

Author keywords

Cardiovascular diseases; Epidemiology; Fasting glucose; Oral glucose tolerance test; Postprandial glucose

Indexed keywords

ACARBOSE; GLUCOSE; ANTIDIABETIC AGENT; INSULIN;

ARTICLE; CARDIOVASCULAR RISK; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; RETINOPATHY; RISK FACTOR; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC DIET; DIET RESTRICTION; METABOLISM; OBESITY; POSTPRANDIAL STATE; RISK ASSESSMENT;

ACARBOSE; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS; DIABETIC DIET; FASTING; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; OBESITY; POSTPRANDIAL PERIOD; RISK ASSESSMENT;

EID: 34248344251     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(06)70478-5     Document Type: Article

References (12)

1. Wolever TM, Chiasson JL, Csima A, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336-40.
2. Balkau B, Bertrais S, Ducimetière P, Eschwège E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999;22:696-9.
3. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
4. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113-8.
5. 1c). Diabetes Care 2003;26:881-5.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
7. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
8. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
9. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-94.
11. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8.
12. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.